Firas B Badin, MD

Newark Beth Israel Med Ctr

University of Damascus School of Medicine

University of Kentucky Medical Center

Newark Beth Israel Med Ctr

American Board of Internal Medicine

American Board of Internal Medicine

• Baptist Health Richmond
• Baptist Health Lexington

• Breast Cancer

  EA1181: Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer)

  Trial Details
• Extensive-stage Small-cell Lung Cancer

  EMERGE 402: Stage IV observational study for adult patients with metastatic SCLC

  Trial Details
• Lung Cancer

  A081801-Alchemist Sub-Study: This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery.

  Trial Details
• Lung Cancer

  Alliance A151216: ALCHEMIST - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

  Trial Details
• Non-small Cell Lung Cancer

  EF-36/Keynote: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

  Trial Details
• Non-small Cell Lung Cancer (NSCLC)

  BeiGene A317-A1217-302: A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, or Metastatic Non-Small Cell Lung Cancer

  Trial Details
• Non-small Cell Lung Cancer (NSCLC)

  Pacific 9: A Phase III, double-blind, placebo-controlled, Randomized, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy

  Trial Details
• Non-small Cell Lung Cancer (NSCLC) (WIRB-22-0106)

  Skyscraper: A Phase II/III, Randomized, Double Blind, Placebo-Controlled Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab

  Trial Details
• NSC Lung Cancer

  Razor-Encore - A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay

  Trial Details
• Previously Treated Non-Small Cell Lung Cancer

  LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

  Trial Details
• Small Cell Lung Carcinoma

  MK3475-B98: A Phase 1b/2 Study to Evaluate Efficacy and Safety of Pembrolizumab in Combination w Investigational Agents for Treatment of Participants With PD-1/L1- refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (Keynote-B

  Trial Details